<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00876928</url>
  </required_header>
  <id_info>
    <org_study_id>Vitamin D-Prediabetes</org_study_id>
    <secondary_id>1-09-CR-15</secondary_id>
    <nct_id>NCT00876928</nct_id>
  </id_info>
  <brief_title>Vitamin D in Minorities With Prediabetes</brief_title>
  <official_title>Effect of Vitamin D Supplementation on Pre-Diabetes in a Minority Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles Drew University of Medicine and Science</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charles Drew University of Medicine and Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D supplementation in minority subjects with both pre-diabetes and low vitamin D
      levels will delay the development of diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Low vitamin D levels 1) are associated with abnormalities in insulin secretion and insulin
      action, 2) predict the development of diabetes in those without diabetes, and 3) are more
      common in people with diabetes. Minority populations (African-Americans and Latinos) are more
      likely to have both low levels of vitamin D and diabetes. This study will identify minority
      individuals who are at increased risk for diabetes (those with central obesity, family
      history of diabetes in first degree relatives and either with hypertension or being treated
      for hypertension), and determine if they have both pre-diabetes, ie, impaired fasting glucose
      and/or impaired glucose tolerance, and low levels of vitamin D. Those that have both will be
      randomized to either high doses of vitamin D or placebo and insulin secretion and action as
      well as changes in the oral glucose tolerance test (reversion to normal, maintenance of
      pre-diabetes or development of diabetes) will be monitored at 3 month intervals for one year.
      This study will test the hypothesis that the increased amount of diabetes in minority
      populations may be due in part to low levels of vitamin D and whether supplementing this
      vitamin may delay the development of diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Subjects Who Develop Diabetes</measure>
    <time_frame>one year</time_frame>
    <description>Diabetes defined by a FPG&gt;=126 mg/dl or a 2-hr glucose concentration on an OGTT of &gt;=200 mg/dl</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disposition Index</measure>
    <time_frame>Baseline, 3, 6, 9, 12 months</time_frame>
    <description>Measure of insulin secretion multiplied by measure of insulin sensitivity,both derived from oral glucose tolerance test; higher values are better</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Pre-diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects with low vitamin D levels and pre-diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with low vitamin D levels and pre-diabetes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin D</intervention_name>
    <description>liquid vitamin D3 dissolved in medium chain triglyceride once a week</description>
    <arm_group_label>vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>medium chain triglyceride given once per week</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age greater than 40.

          2. Impaired fasting glucose (FPG level greater than 100 and less than 126 mg/dl); and/or

          3. Impaired glucose tolerance (2-h plasma glucose concentration after 75 gram glucose
             load greater than 140 and less than 200 mg/dl)

          4. Serum 25-OHD less than 30 ng/ml

          5. Able and willing to provide informed consent

        Exclusion Criteria:

          1. FPG greater than 126 mg/dl or 2-hour-OGTT plasma glucose greater than 200 mg/dl

          2. Major psychiatric disorder on medication (excluding successfully treated depression)

          3. Diagnosed diabetes mellitus

          4. HIV/AIDS

          5. Major hematological, hepatic (AST/ALT levels greater than or equal to 2 times normal)
             or renal eGFR less than 60 ml/min) disorder

          6. History of carcinoma, except skin basal cell or squamous cell skin carcinomas

          7. Heart failure, unstable angina or history of a myocardial infarction

          8. Alcohol or substance abuse

          9. Current treatment with glucocorticoids

         10. Current treatment with diabetes medications, including metformin

         11. Cushing's syndrome

         12. Primary hyperparathyroidism

         13. Nephrolithiasis

         14. Pregnancy or breast-feeding

         15. Regular visits to a tanning salon (unlikely in this minority population)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mayer B. Davidson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles Drew University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charles Drew University</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2009</study_first_submitted>
  <study_first_submitted_qc>April 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2009</study_first_posted>
  <results_first_submitted>July 3, 2012</results_first_submitted>
  <results_first_submitted_qc>April 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 14, 2013</results_first_posted>
  <last_update_submitted>April 17, 2013</last_update_submitted>
  <last_update_submitted_qc>April 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charles Drew University of Medicine and Science</investigator_affiliation>
    <investigator_full_name>Mayer Davidson</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>pre-diabetes</keyword>
  <keyword>minorities</keyword>
  <keyword>oral glucose tolerance test</keyword>
  <keyword>disposition index</keyword>
  <keyword>insulin secretion</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Subjects with low vitamin D levels and pre-diabetes
Medium chain triglyceride given once per week</description>
        </group>
        <group group_id="P2">
          <title>Vitamin D</title>
          <description>Subjects with low vitamin D levels and pre-diabetes
Liquid vitamin D3 dissolved in medium chain triglyceride once per week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hypokalemia-affects insulin secretion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Subjects with low vitamin D levels and pre-diabetes</description>
        </group>
        <group group_id="B2">
          <title>Vitamin D</title>
          <description>Subjects with low vitamin D levels and pre-diabetes</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="117"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.5" spread="7.0"/>
                    <measurement group_id="B2" value="52.3" spread="8.0"/>
                    <measurement group_id="B3" value="52.4" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Subjects Who Develop Diabetes</title>
        <description>Diabetes defined by a FPG&gt;=126 mg/dl or a 2-hr glucose concentration on an OGTT of &gt;=200 mg/dl</description>
        <time_frame>one year</time_frame>
        <population>Minorities with pre-diabetes and hypovitaminosis D</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects with low vitamin D levels and pre-diabetes</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D</title>
            <description>Subjects with low vitamin D levels and pre-diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects Who Develop Diabetes</title>
          <description>Diabetes defined by a FPG&gt;=126 mg/dl or a 2-hr glucose concentration on an OGTT of &gt;=200 mg/dl</description>
          <population>Minorities with pre-diabetes and hypovitaminosis D</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is that there is no effect of vitamin D on the development of diabetes in people with pre-diabetes and hypovitaminosis D. There were no published data when this trial was started on the effect of vitamin D in pre-diabetes making a power calculation difficult.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.61</p_value>
            <p_value_desc>A chi square test was used for the number of participants developing diabetes and a 2-way repeated measures ANOVA for the disposition index</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Percent of patients developing diabetes</param_type>
            <param_value>10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8</ci_lower_limit>
            <ci_upper_limit>12</ci_upper_limit>
            <estimate_desc>Primary outcome compared the number of participants developing diabetes after receiving vitamin D or placebo for one year. Secondary outcome compared changes in 2-way repeated measures ANOVA; therefore,no confidence intervals/dispersion parameters</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disposition Index</title>
        <description>Measure of insulin secretion multiplied by measure of insulin sensitivity,both derived from oral glucose tolerance test; higher values are better</description>
        <time_frame>Baseline, 3, 6, 9, 12 months</time_frame>
        <population>modified intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subjects with low vitamin D levels and pre-diabetes</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D</title>
            <description>Subjects with low vitamin D levels and pre-diabetes</description>
          </group>
        </group_list>
        <measure>
          <title>Disposition Index</title>
          <description>Measure of insulin secretion multiplied by measure of insulin sensitivity,both derived from oral glucose tolerance test; higher values are better</description>
          <population>modified intent to treat</population>
          <units>Unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dispostion Index at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.5" lower_limit="1.3" upper_limit="1.6"/>
                    <measurement group_id="O2" value="1.3" spread="0.4" lower_limit="1.2" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disposition Index at 3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.8"/>
                    <measurement group_id="O2" value="1.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disposition Index at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.6"/>
                    <measurement group_id="O2" value="1.2" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disposition Index at 9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.6"/>
                    <measurement group_id="O2" value="1.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disposition Index at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.6"/>
                    <measurement group_id="O2" value="1.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there would be no difference in the changes in the Disposition Index between the 2 groups over the year.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.39</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Subjects with low vitamin D levels and pre-diabetes</description>
        </group>
        <group group_id="E2">
          <title>Vitamin D</title>
          <description>Subjects with low vitamin D levels and pre-diabetes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mayer B. Davidson, MD</name_or_title>
      <organization>Charles R. Drew University</organization>
      <phone>323 357-3439</phone>
      <email>mayerdavidson@cdrewu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

